TABLE 1
FROM:
Fluvastatin and Atorvastatin: A comparison of patent protection (Part 2)
Leighton Howard
BACK TO ARTICLETable 1. (a) Atorvastatin key patents and (b) Fluvastatin key patents
| Applicant | Priority application | Claims coverage |
|---|---|---|
| (a) | ||
| Warner Lambert | US-1986-0868867 30/05/1986 | Atorvastatin active ingredient — generic formula (racemate). |
| Warner Lambert | US-1989-0384187 21/07/1989 | Atorvastatin active ingredient — specific formula (enantiomer) and hemicalcium salt thereof. |
| Sandoz | US-1991-0805667 12/12/1991 | Formulation of a statin comprising an alkaline medium capable of imparting a pH of 8 or higher to an aqueous solution or dispersion of the composition. |
| Warner Lambert | US-1993-0005708 19/01/1993 | Stable, oral formulation comprising Atorvastatin hemicalcium salt and a metal salt additive. |
| Warner Lambert | US-1995-0001452 17/07/1995 | Crystalline Forms I, II and IV of Atorvastatin and hydrates. |
| Pfizer | EP-1998-0936587 11/08/1998 | Combination of Atorvastatin and Amlodipine for treatment of hypertension and hyperlipidemia. |
| (b) | ||
| Sandoz | US-1982-0443668 22/11/1982 | Fluvastatin active ingredient. |
| Sandoz | US-1991-0805667 12/12/1991 | Formulation of a statin comprising an alkaline medium capable of imparting a pH of 8 or higher to an aqueous solution or dispersion of the composition. |
| Astra (reassigned to Novartis) | SE-1996-0003667 08/10/1996 | Pharmaceutical composition for sustained release comprising a water-soluble salt of Fluvastatin in a matrix formulation, or diffusion-controlled membrane coated formulation. |
| Novartis | US-2000-0549222 13/04/2000 | Sustained-release tablet containing granules of <200 microns that comprise Fluvastatin and a hydroxypropyl methyl cellulose polymer. |
